Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
The stock price of Health Yuan, a constituent stock of the CSI 50 Technology Strategy Index, has hit a multi-year high.
Published Time：
2020-06-09
Since the beginning of 2020, technology-related themes have remained a focus of investor attention and investment in the capital market. From pharmaceutical innovation and semiconductor chips to 5G communication and artificial intelligence, many high-tech fields have received relatively sustained market attention. Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan") has achieved outstanding performance in the greater health sector, not only ranking among the constituent stocks of the CSI 50 Technology Strategy Index, but its stock price has also hit record highs in recent years.
It is understood that the CSI 50 Technology Strategy Index selects stocks in the high-tech field with sustained technological innovation capabilities, reasonable incentive mechanisms, and sound fundamentals from Shanghai and Shenzhen A-shares. The index aims to reflect the overall performance of this type of A-share listed company, with the code 931186. Based on December 31, 2012, with a base point of 1000, it only has 50 constituent stocks, and Health Yuan, whose recent stock price trend has been quite eye-catching, is among them.
After years of operation and development, Health Yuan has established diversified and multi-layered R&D institutions, with strong R&D capabilities and international R&D concepts in the fields of chemical and traditional Chinese medicine preparations, biological drugs, diagnostic reagents, health products, and food. The company's product pipeline is clearly focused on areas such as antimicrobials, anti-tumor, gonadotropins, digestion, nerves, and respiration. By actively introducing senior domestic and foreign experts and innovative talents, increasing R&D investment, and forming overseas strategic alliances, the company has further enhanced its R&D competitiveness. In addition, the successful launch of two inhalers in 2019 has gained Health Yuan continued attention from many investors.
It is understood that 2020 is a key year for Health Yuan's transformation and deepening. The company will seize the rare strategic opportunity of technological innovation, continuously promote the improvement of pharmaceutical R&D capabilities, establish leading medical technology capabilities with high thresholds and barriers, and serve national interests and people's livelihood and care for public health.
As of press time, Health Yuan's stock price has broken through the 14 yuan mark. However, based on the current relatively low valuation of this stock, from the perspective of long-term investment value, many securities firms continue to be optimistic about Health Yuan's development prospects and give it a "buy" rating.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.